ATTOVIA THERAPEUTICS INC

Attovia Therapeutics (ATTO) trades below its 200‑day SMA, offering a potential value entry amid a promising oncology pipeline and recent market rebound potential.

Attovia Therapeutics dips 1% to $14.05 amid a 32% monthly slide, low trading volume and a high 200‑day SMA gap—investors weigh risk vs. a possible breakthrough.

Attovia Therapeutics (ATTO) gains 1.17% to $14.04—market cap $626.8M—while the 200‑day SMA drops to $19.78, hinting at upside if biotech sentiment rebounds.

Attovia Therapeutics falls 34.8% as thin volume and a 200‑day SMA gap warn investors—why the biotech’s rally feels shaky and risky.